Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2007 | 1 |
2018 | 1 |
2020 | 2 |
2021 | 1 |
2022 | 2 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Did you mean
may s allen[Author]
(1 results)?
Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
Oncogene. 2022 May;41(21):2973-2983. doi: 10.1038/s41388-022-02305-x. Epub 2022 Apr 22.
Oncogene. 2022.
PMID: 35459782
Free PMC article.
Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma.
Schreck KC, Morin A, Zhao G, Allen AN, Flannery P, Glantz M, Green AL, Jones C, Jones KL, Kilburn LB, Nazemi KJ, Samuel D, Sanford B, Solomon DA, Wang J, Pratilas CA, Nicolaides T, Mulcahy Levy JM.
Schreck KC, et al. Among authors: allen an.
Clin Cancer Res. 2021 Nov 15;27(22):6197-6208. doi: 10.1158/1078-0432.CCR-21-2660. Epub 2021 Aug 25.
Clin Cancer Res. 2021.
PMID: 34433654
Free PMC article.
Item in Clipboard
Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
Odeniyide P, Yohe ME, Pollard K, Vaseva AV, Calizo A, Zhang L, Rodriguez FJ, Gross JM, Allen AN, Wan X, Somwar R, Schreck KC, Kessler L, Wang J, Pratilas CA.
Odeniyide P, et al. Among authors: allen an.
Oncogene. 2022 May;41(21):3037. doi: 10.1038/s41388-022-02342-6.
Oncogene. 2022.
PMID: 35534540
Free PMC article.
No abstract available.
Item in Clipboard
Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma.
Schreck KC, Allen AN, Wang J, Pratilas CA.
Schreck KC, et al. Among authors: allen an.
Neurooncol Adv. 2020 Oct 15;2(1):vdaa138. doi: 10.1093/noajnl/vdaa138. eCollection 2020 Jan-Dec.
Neurooncol Adv. 2020.
PMID: 33235998
Free PMC article.
Item in Clipboard
Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.
Wang J, Pollard K, Allen AN, Tomar T, Pijnenburg D, Yao Z, Rodriguez FJ, Pratilas CA.
Wang J, et al. Among authors: allen an.
Cancer Res. 2020 Dec 1;80(23):5367-5379. doi: 10.1158/0008-5472.CAN-20-1365. Epub 2020 Oct 8.
Cancer Res. 2020.
PMID: 33032988
Free PMC article.
Item in Clipboard
A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.
Wang J, Yao Z, Jonsson P, Allen AN, Qin ACR, Uddin S, Dunkel IJ, Petriccione M, Manova K, Haque S, Rosenblum MK, Pisapia DJ, Rosen N, Taylor BS, Pratilas CA.
Wang J, et al. Among authors: allen an.
Cancer Discov. 2018 Sep;8(9):1130-1141. doi: 10.1158/2159-8290.CD-17-1263. Epub 2018 Jun 7.
Cancer Discov. 2018.
PMID: 29880583
Free PMC article.
Item in Clipboard
A role for mammalian target of rapamycin in regulating T cell activation versus anergy.
Zheng Y, Collins SL, Lutz MA, Allen AN, Kole TP, Zarek PE, Powell JD.
Zheng Y, et al. Among authors: allen an.
J Immunol. 2007 Feb 15;178(4):2163-70. doi: 10.4049/jimmunol.178.4.2163.
J Immunol. 2007.
PMID: 17277121
Item in Clipboard
Cite
Cite